Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype

H. Iwamoto, A. Yokoyama, N. Shiota, H. Shoda, Y. Haruta, N. Hattori, N. Kohno
European Respiratory Journal 2008 31: 1379-1380; DOI: 10.1183/09031936.00014108
H. Iwamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Yokoyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Shiota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Shoda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Haruta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Hattori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Kohno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Although currently available asthma medications are very effective in the majority of cases, there remains a subgroup for which disease control is difficult. Anticholinergics have long been used to treat asthma, although their current role in therapy is supplementary 1. Tiotropium bromide, a recently developed anticholinergic, is a long-acting bronchodilator with a well-established effectiveness for treating chronic obstructive pulmonary disease 2. Although some subgroups of asthmatics seem to respond better to anticholinergics, the pathophysiological features of these responders have yet to be established 3, 4. Previous studies that aimed to identify asthma subgroups which respond better to anticholinergics have suggested the following clinical features: patients with nocturnal symptoms, chronic asthma showing concurrent fixed airway obstruction, intrinsic asthma with longer duration of disease and nonatopic asthma 1, 5. The objective of the present study was to determine the characteristics of asthmatics which show good responses to tiotropium bromide.

We investigated the efficacy of tiotropium bromide in 17 asthmatic patients followed in an outpatient setting at Hiroshima University Hospital (Hiroshima, Japan). Consecutive patients were selected with severe persistent asthma diagnosed and classified according to Global Initiative for Asthma guidelines 6. The study was approved by the local ethics committee and written informed consent was obtained from all subjects.

Subject characteristics are shown in table 1⇓. All patients were treated with inhaled corticosteroids equivalent to 800–1,600 μg·day−1 of budesonide. Other anti-asthma medications were also prescribed, including 5–20 mg·day−1 of oral corticosteroid (23.5%). All subjects had tried a long-acting β2-agonist (LABA) but six (35.3%) stopped administration due to ineffectiveness or adverse events. The remaining subjects continued using LABA.

View this table:
  • View inline
  • View popup
Table 1—

Subject characteristics

Induced sputum was obtained prior to tiotropium bromide administration. Induced sputum was collected for 5 min after each 5-min inhalation of 3, 4 and 5% hypertonic saline for a total of 30 min. Lung function tests were performed before and 4 weeks after tiotropium administration. The efficacy of tiotropium bromide was assessed through the change in forced expiratory volume in one second (ΔFEV1). ΔFEV1 following add-on therapy with tiotropium bromide was analysed using the Wilcoxon signed-rank test. Associations between measured variables were examined using Spearman's rank correlation test.

Tiotropium bromide administration for 4 weeks was well tolerated by all subjects and FEV1 improved significantly (p = 0.001). There were no significant correlations between ΔFEV1 and demographic or clinical variables including age, sex, body mass index, smoking history, atopic status, disease duration, and use of particular anti-asthmatic drugs, such as LABA and leukotriene receptor antagonist (data not shown).

The percentages of eosinophils in induced sputum were inversely correlated with ΔFEV1 (fig. 1a⇓). The proportions of neutrophils were positively correlated with ΔFEV1 (fig. 1b⇓). We also analysed subjects who had never smoked (n = 8) and former or current smokers (n = 9) separately because smoking has been associated with changes in cell types of induced sputum 7. In addition, restriction to subjects who had never smoked could exclude the confounding effects of COPD, which may be complicated in smoking asthmatics. The analysis of eight subjects who had never smoked showed comparable correlations between eosinophils or neutrophils and ΔFEV1.

Fig. 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1—

Spearman rank correlations (rS) between the change in forced expiratory volume in one second (ΔFEV1) after 4 weeks of tiotropium bromide administration and a) eosinophil percentages or b) neutrophil percentages in induced sputum. Eosinophil and neutrophil percentages were determined prior to tiotropium bromide administration. In all subjects a) rS = -0.669, p = 0.003 and b) rS = 0.540, p = 0.025. In smokers a) rS = -0.706, p = 0.034 and b) rS = 0.361, p = 0.339. In nonsmokers a) rS = -0.762, p = 0.028 and b) rS = 0.762, p = 0.028. ○: smokers; •: nonsmokers.

The results of this investigation suggest associations between responsiveness to tiotropium bromide and types of inflammatory cells in the induced sputum of patients with severe persistent asthma treated with moderate-to-high doses of inhaled corticosteroids and other anti-asthma agents. Comparable results from nonsmoking and smoking asthmatics indicate a rationale for using tiotropium bromide to treat severe asthma with a noneosinophilic sputum profile.

The differences in clinical responses to anti-asthma drugs might be associated with the heterogeneous nature of asthma 1, 8. Evidence indicates considerable heterogeneity of airway inflammation in severe asthma 9. The most well-recognised pattern is noneosinophilic asthma, possibly associated with neutrophil influx and activation 9. The associations between induced sputum cells and clinical responses to anti-asthma drugs are well documented: an eosinophilic profile was reported to be associated with a better response to corticosteroids 8. The results of this preliminary study indicate that the induced sputum profile could also help to distinguish tiotropium bromide responders in severe persistent asthmatics: a noneosinophilic sputum profile is associated with a better response to tiotropium bromide. This observation warrants validation by further clinical investigation.

Support statement

This study was partly supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004;3:CD003269
      OpenUrlPubMed
    2. ↵
      Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of COPD: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–555.
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996;154:876–880.
      OpenUrlPubMedWeb of Science
    4. ↵
      Fardon T, Haggart K, Lee DK, Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007;101:1218–1228.
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006;533:36–39.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Global Initiative for Asthma (GINA) Executive Committee. Global Strategy for Asthma Management and Prevention. GINA 2006. www.ginasthma.com Date last updated: November 2006. Date last accessed: October 16, 2007
    7. ↵
      Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. Chest 2001;120:1917–1922.
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 2007;119:1043–1052.
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001;119:1329–1336.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 31 Issue 6 Table of Contents
    European Respiratory Journal: 31 (6)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype
    H. Iwamoto, A. Yokoyama, N. Shiota, H. Shoda, Y. Haruta, N. Hattori, N. Kohno
    European Respiratory Journal Jun 2008, 31 (6) 1379-1380; DOI: 10.1183/09031936.00014108

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype
    H. Iwamoto, A. Yokoyama, N. Shiota, H. Shoda, Y. Haruta, N. Hattori, N. Kohno
    European Respiratory Journal Jun 2008, 31 (6) 1379-1380; DOI: 10.1183/09031936.00014108
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Support statement
      • Statement of interest
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Treatable traits approach in interstitial lung disease
    • Reply: Treatable traits approach in interstitial lung disease
    • TB screening in migrants to the EU/EEA and UK
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society